| Year | Title | Author(s) |
|---|
| 2013 |
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription
Blood |
Thomas, D Powell, JA Vergez, F Segal, DH Nguyen, NYN Baker, A Teh, TC Barry, EF Sarry, JE Lee, EM Nero, TL Jabbour, AM Pomilio, G Green, BD Manenti, S Glaser, SP Parker, MW Lopez, AF Ekert, PG Lock, RB Huang, DCS Nilsson, SK Recher, C Wei, AH Guthridge, MA |
| 2015 |
Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma
Clin. Cancer Res. |
Gupte, A Baker, EK Wan, SS Stewart, E Loh, A Shelat, AA Gould, CM Chalk, AM Taylor, S Lackovic, K Karlstrom, A Mutsaers, AJ Desai, J Madhamshettiwar, PB Zannettino, ACW Burns, C Huang, DCS Dyer, MA Simpson, KJ Walkley, CR |
| 2015 |
A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production
Nature Communications |
Nachbur, U Stafford, CA Bankovacki, A Zhan, YF Lindqvist, LM Fiil, BK Khakham, Y Ko, HJ Sandow, JJ Falk, H Holien, JK Chau, D Hildebrand, J Vince, JE Sharp, PP Webb, AI Jackman, KA Muhlen, S Kennedy, CL Lowes, KN Murphy, JM Gyrd-Hansen, M Parker, MW Hartland, EL Lew, AM Huang, DCS Lessene, G Silke, J |
| 2017 |
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax
Blood |
Anderson, MA Tam, C Lew, TE Juneja, S Juneja, M Westerman, D Wall, M Lade, S Gorelik, A Huang, DCS Seymour, JF Roberts, AW |
| 2017 |
Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors
Acs Med. Chem. Lett. |
Sharp, PP Garnier, JM Hatfaludi, T Xu, Z Segal, D Jarman, KE Jousset, H Garnham, A Feutrill, JT Cuzzupe, A Hall, P Taylor, S Walkley, CR Tyler, D Dawson, MA Czabotar, P Wilks, AF Glaser, S Huang, DCS Burns, CJ |
| 2019 |
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
Nat. Med. |
Agarwal, R Chan, YC Tam, CS Hunter, T Vassiliadis, D Teh, CE Thijssen, R Yeh, P Wong, SQ Ftouni, S Lam, EYN Anderson, MA Pott, C Gilan, O Bell, CC Knezevic, K Blombery, P Rayeroux, K Zordan, A Li, J Huang, DCS Wall, M Seymour, JF Gray, DHD Roberts, AW Dawson, MA Dawson, SJ |
| 2020 |
Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells
Cell Death And Differentiation |
Thijssen, R Alvarez-Diaz, S Grace, C Gao, MY Segal, DH Xu, Z Strasser, A Huang, DCS |